S&P 500   3,851.43 (-0.49%)
DOW   31,429.75 (+0.12%)
QQQ   313.98 (-1.39%)
AAPL   124.22 (-0.72%)
MSFT   230.37 (-1.50%)
FB   258.47 (-0.20%)
GOOGL   2,035.45 (-1.41%)
TSLA   682.53 (-0.57%)
AMZN   3,054.77 (-1.28%)
NVDA   522.37 (-2.59%)
BABA   236.98 (+1.09%)
CGC   34.46 (-2.24%)
GE   13.44 (+3.54%)
MU   91.14 (+0.05%)
NIO   43.62 (+0.76%)
AMD   82.80 (-1.58%)
T   28.44 (+0.78%)
F   12.29 (-2.07%)
ACB   10.75 (-2.54%)
DIS   194.84 (+0.46%)
BA   232.34 (+4.12%)
NFLX   528.02 (-3.61%)
PFE   33.85 (+1.01%)
S&P 500   3,851.43 (-0.49%)
DOW   31,429.75 (+0.12%)
QQQ   313.98 (-1.39%)
AAPL   124.22 (-0.72%)
MSFT   230.37 (-1.50%)
FB   258.47 (-0.20%)
GOOGL   2,035.45 (-1.41%)
TSLA   682.53 (-0.57%)
AMZN   3,054.77 (-1.28%)
NVDA   522.37 (-2.59%)
BABA   236.98 (+1.09%)
CGC   34.46 (-2.24%)
GE   13.44 (+3.54%)
MU   91.14 (+0.05%)
NIO   43.62 (+0.76%)
AMD   82.80 (-1.58%)
T   28.44 (+0.78%)
F   12.29 (-2.07%)
ACB   10.75 (-2.54%)
DIS   194.84 (+0.46%)
BA   232.34 (+4.12%)
NFLX   528.02 (-3.61%)
PFE   33.85 (+1.01%)
S&P 500   3,851.43 (-0.49%)
DOW   31,429.75 (+0.12%)
QQQ   313.98 (-1.39%)
AAPL   124.22 (-0.72%)
MSFT   230.37 (-1.50%)
FB   258.47 (-0.20%)
GOOGL   2,035.45 (-1.41%)
TSLA   682.53 (-0.57%)
AMZN   3,054.77 (-1.28%)
NVDA   522.37 (-2.59%)
BABA   236.98 (+1.09%)
CGC   34.46 (-2.24%)
GE   13.44 (+3.54%)
MU   91.14 (+0.05%)
NIO   43.62 (+0.76%)
AMD   82.80 (-1.58%)
T   28.44 (+0.78%)
F   12.29 (-2.07%)
ACB   10.75 (-2.54%)
DIS   194.84 (+0.46%)
BA   232.34 (+4.12%)
NFLX   528.02 (-3.61%)
PFE   33.85 (+1.01%)
S&P 500   3,851.43 (-0.49%)
DOW   31,429.75 (+0.12%)
QQQ   313.98 (-1.39%)
AAPL   124.22 (-0.72%)
MSFT   230.37 (-1.50%)
FB   258.47 (-0.20%)
GOOGL   2,035.45 (-1.41%)
TSLA   682.53 (-0.57%)
AMZN   3,054.77 (-1.28%)
NVDA   522.37 (-2.59%)
BABA   236.98 (+1.09%)
CGC   34.46 (-2.24%)
GE   13.44 (+3.54%)
MU   91.14 (+0.05%)
NIO   43.62 (+0.76%)
AMD   82.80 (-1.58%)
T   28.44 (+0.78%)
F   12.29 (-2.07%)
ACB   10.75 (-2.54%)
DIS   194.84 (+0.46%)
BA   232.34 (+4.12%)
NFLX   528.02 (-3.61%)
PFE   33.85 (+1.01%)
Log in
OTCMKTS:EMMA

Emmaus Life Sciences Stock Forecast, Price & News

$1.52
+0.07 (+4.83 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.41
Now: $1.52
$1.85
50-Day Range
$1.19
MA: $1.46
$1.83
52-Week Range
$0.70
Now: $1.52
$2.16
Volume52,386 shs
Average Volume18,146 shs
Market Capitalization$74.46 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34
Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EMMA
CUSIPN/A
CIKN/A
Phone310-214-0065
Employees28
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.32 million

Profitability

Miscellaneous

Market Cap$74.46 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.17 out of 5 stars

Medical Sector

1777th out of 1,969 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

21st out of 25 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$1.52
+0.07 (+4.83 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EMMA News and Ratings via Email

Sign-up to receive the latest news and ratings for EMMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Emmaus Life Sciences (OTCMKTS:EMMA) Frequently Asked Questions

What stocks does MarketBeat like better than Emmaus Life Sciences?

Wall Street analysts have given Emmaus Life Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Emmaus Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Emmaus Life Sciences' stock price been impacted by COVID-19 (Coronavirus)?

Emmaus Life Sciences' stock was trading at $2.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EMMA shares have decreased by 45.1% and is now trading at $1.52.
View which stocks have been most impacted by COVID-19
.

Who are Emmaus Life Sciences' key executives?

Emmaus Life Sciences' management team includes the following people:
  • Dr. Yutaka Niihara M.P.H., M.D., M.P.H, Chairman & CEO (Age 61, Pay $385k)
  • Mr. Willis C. Lee, Vice Chairman & COO (Age 61, Pay $240k)
  • Ms. Lan T. Tran M.P.H., M.P.H, Pres & Chief Admin. Officer (Age 45, Pay $235k)
  • Mr. Yasushi Nagasaki CPA, CPA, Interim Chief Financial Officer (Age 54, Pay $235k)
  • Mr. Kurt H. Kruger M.B.A., M.S., Consultant (Age 66, Pay $300.02k)
  • Mr. George Sekulich, Sr. VP of Global Commercialization & Chief Information Officer
  • Mr. Dale E. Short J.D., Gen. Counsel
  • Dr. Charles W. Stark Pharm.D., Pharm.D, Sr. VP of Medical Affairs (Age 66)
  • Mr. S. Steven Lee, Independent Consultant (Age 55)

Who are some of Emmaus Life Sciences' key competitors?

What is Emmaus Life Sciences' stock symbol?

Emmaus Life Sciences trades on the OTCMKTS under the ticker symbol "EMMA."

How do I buy shares of Emmaus Life Sciences?

Shares of EMMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emmaus Life Sciences' stock price today?

One share of EMMA stock can currently be purchased for approximately $1.52.

How much money does Emmaus Life Sciences make?

Emmaus Life Sciences has a market capitalization of $74.46 million and generates $1.32 million in revenue each year.

How many employees does Emmaus Life Sciences have?

Emmaus Life Sciences employs 28 workers across the globe.

What is Emmaus Life Sciences' official website?

The official website for Emmaus Life Sciences is www.emmausmedical.com.

Where are Emmaus Life Sciences' headquarters?

Emmaus Life Sciences is headquartered at 21250 Hawthorne Boulevard Suite 800, Torrance CA, 90503.

How can I contact Emmaus Life Sciences?

Emmaus Life Sciences' mailing address is 21250 Hawthorne Boulevard Suite 800, Torrance CA, 90503. The company can be reached via phone at 310-214-0065 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.